1 / 33

Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy

NAPLES III N ovel A pproaches in P reventing or L imiting E vent III Tria L Randomised Comparison of Bivalirudin versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting thought the Femoral Approach.

lindsey
Télécharger la présentation

Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NAPLES IIINovel Approaches in Preventing or Limiting Event III TriaLRandomisedComparisonofBivalirudin versus UnfractionatedHeparin in Patients at High RiskofBleedingUndergoingElectiveCoronaryStentingthought the FemoralApproach Carlo Briguori, MD, FACC, FSCAIClinica Mediterranea, Naples, Italy

  2. I, Carlo Briguori DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. Disclosure Statement of Financial Interest

  3. Background • Major bleeding and blood transfusion after PCI have been strongly associated with increased rates of in-hospital and late mortality, myocardial infarction (MI) and repeat revascularization1-2 • Unfractionated heparin (UFH) is the most commonly used anticoagulant drug during PCI in order to prevent thrombotic complications • Limitations of UFH include4-5 • inability to inactivate clot-bound thrombin, • the indirect mechanism of thrombin inhibition via anti-thrombin-III activation, • the nonspecific protein binding • Non-linear pharmacokinetic, requiring a continuous monitoring of the effect in order to confirm the optimal anticoagulation regimen and, on the contrary, avoid a high bleeding risk 1 Doyle BJ et al. J Am CollCardiol 2009;53:2019-27 2 Rao SV. et al. Am Heart J 2008;155:369-74 3.Young E, et al. Thrombosis and Haemostasis1992; 67:639-43. 4. Sobel M et al. J VascSurg2001;33:587-94

  4. Background • Bivalirudin (The Medicine’s Co., Parsippany, NJ) is a synthetic direct thrombin inhibitor approved for patients with stable and unstable coronary syndromes undergoing PCI1. • Favorable properties of bivalirudin include: • its ability to inhibit both circulating and clot-bound thrombin, • an inherent anti-platelet effect by inhibition of thrombin-induced platelet activation, • ashort half-life, which may minimize bleeding. • direct binding to thrombin without co-factors and no binding to plasma proteins. • linear kinetics, resulting in predictable serum concentrations2-4 1. Levine GN et al. J Am CollCardiol2011;58:e44 2. Stone GW et al. JAMA 2007;298:2497 3. Stone GW, et al. N Engl J Med 2008;358:2218 4. Lincoff AM et al. JAMA 2003;298;853

  5. Background • The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3 trial1showed that bivalirudin led to a net clinical outcome comparable with that achieved with UFH. However: • an high (140 U/Kg) single bolus dose of UFH was used • Not specifically designed for high-risk bleeding patients • The ISAR-REACT 3A2showed that, in biomarker negative patients, a low dosing regimen (100 U/Kg) of UFH represents a simple and safe method of lowering the bleeding peri-procedural risk without compromise the risk of ischemic complications. However: • Single-arm prospective study • Not specifically designed for high-risk bleeding patients 1. Kastrati et al. N Engl J Med 2008;359:688-96 2. Schultz S et al. Eur Heart J 2010;31:582-7

  6. High risk bleeding patients Nikolski E et al EurHeart J2007; 28:1936-45

  7. Background • At present there is a lack of prospective clinical trial assessing the safety and the efficacy of bivalirudin compared with UFH in the subset of patients exposed to high risk of bleeding.

  8. Purpose • We performed a prospective, randomized, double-blind, single center, investigator-initiated study comparing the 2 different strategies in high-risk bleeding patients: • Unfractionated heparin (UFH Group) • Bivalirudin (Bivalirudin Group)

  9. NAPLES III trial • DESIGN: Prospective, randomized, double-blind single center, investigator-initiated clinical study Elective PCI in biomarker negative patients at high risk of bleeding (risk score ≥10) Bivalirudin group UFH group In-hospital major bleeding

  10. Hypothesis: Reduction in the primary endpoint from >5%1-3in the UFH group to <3%2-3in the Bivalirudin group Sample size: A total of 830 patients (415 each group) will be necessary to gave the study 80% power and a significance level <0.05 Sample size 1. Nikolski E et al. Eur Heart J 2007; 28:1936-45 2. Kastrati A et al. N Engl J Med 2008;359:688-96 3. Schultz S et al. Eur Heart J 2010;31:582-7

  11. Inclusioncriteria • Age 18 y • Bleeding risk score ≥10 • Procedure planned through the femoral approach • Angiographic evidence of de novo or restenotic lesions requiring revascularization • Stable or unstable angina or documented silent ischemia • Negative biomarkers of myocardial injury • Double antiplatelet therapy • Stable hemodynamic conditions

  12. Exclusion criteria • Bleeding risk score <10 • Pregnancy • Ongoing or recent (<48 h) episode of STEMI or NSTEMI • Negative biomarkers of myocardial injury • Chronic dialysis and/or history or previous dialysis • Hemodynamic instability requiring inotropic support or IABP • Ongoing or recent (<7 days) treatment with glycoprotein IIb/IIIa inhibitors • Ongoing or recent (6 months) bleeding or bleeding diathesis. • Recent (within 6 months) stroke • History of heparin-induced thrombocitopenia • Platelet count <100.000/mm3

  13. NAPLES III trial UFH group Bivalirudin group 70 U/Kg i.v.priorto start the procedure Additionalbolus 20 U/Kg in case ACT <250 sec Bolus of 0.75 mg/kg i.v. prior to the start of the procedure, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure Additionalbolus 0.3mg/Kg in case ACT <250 sec

  14. Primary endpoint: Rate of in-hospital major bleeding, defined according the REPLACE 2 criteria: intracranial, intraocular, retroperitoneal, access-site haemorrhage requiring intervention, clinically overt blood loss resulting in a decrease in haemoglobin by ≥3 g/dl, any decrease in haemoglobin ≥4 g/dl, transfusion of ≥2 units of packed cells or whole blood Endpoints

  15. Secondary endpoints: Rate of in-hospital major and minor bleeding, defined according the REPLACE 2 criteria Rate of in-hospital, 30-day and 1-year major adverse cardiac events, defined as death, non-fatal myocardial infarction, repeat revascularization Rate of stent thrombosis, according to the ARC criteria Rate of major bleeding according to other criteria Endpoints

  16. Assessed for eligibility ( n= 1859) • Exclusion (n = 1021) • Not meeting inclusion/exclusion criteria (n = 998) • Radial access (n = 275) • Acute myocardial infarction (n = 219) • End-stage renal disease = 238) • IIbIIIa inhibitors (n = 211) • Recent bleeding (n = 55) • Refused to partecipate (n = 23) Enrollement Randomized (n = 837) • Patients allocated in the Bivalirudin Group (n = 418) • Received allocated treatment (n = 418) • Did not receive the allocated treatment (n =0) • Patients allocated in the UFH group (n = 419) • Received allocated treatment (n = 419) • Did not receive the allocated treatment (n= 0) Allocation Patients lost at follow-up (n = 0) Discontinued treatement (n = 0) Patients lost at follow-up (n = 0) Discontinued treatment (n = 0) Follow-up Analysis Patients analized ( n = 418) Patients excluded from analysis (n = 0) Patients analized ( n 419) Patients excluded from analysis (n = 0)

  17. Clinical Characteristics

  18. Procedural Characteristics

  19. Procedural Characteristics

  20. Procedural Characteristics

  21. Procedural Characteristics

  22. 16/146 Primaryendpoint Odds ratio = 1.28; 95% CI= 0.58-2.86 p = 0.54 14/418 3.3% 3,5 3,0 14/418 2.6% 2,5 11/419 2,0 % 1,5 1,0 0,5 0,0 UFH group Bivalirudin group

  23. Primary endpoint

  24. Primaryendpoint p = 0.80 2,5 2.1% UFH group 7/418 9/419 2,0 p = 0.10 1.7% 1.7% 7/418 7/418 1,5 % 1,0 0.5% 0,5 2/419 0,0 Entry-site Non entry-site Bivalirudin group

  25. Secondary endpoint

  26. Allbleeding(major and minor) 10.0 Odds ratio = 0.88; 95% CI= 0.55-1.44; p = 0.63 9.1% 9.0 8.1% 38/419 8.0 34/418 % 7.0 UFH group 6.0 5.0 4.0 p = 1.00 6.0 5.2% 5.2% p = 0.56 5.0 22/419 22/418 3.8% 4.0 16/419 % 2.9% 3.0 12/418 2.0 1.0 Bivalirudin group 0 Entry-site Non entry-site

  27. Peak ACT & Bleeding p = 0.36 p = 0.77 380 365±151 364±150 355±141 360 Event yes 340 316±86 320 Event no 300 peak ACT (seconds) 280 260 240 220 200 Major bleeding Major&Minor bleeding

  28. PeriproceduralMyocardialInfarction(TnI >5x ULN) p = 0.93 25 21.8 21.5 90/419 91/418 20 % 15 10 5 0 UFH group Bivalirudin group

  29. Secondary endpoint30-day MACE

  30. Secondary endpoint1-year MACE

  31. Conclusions • In patients at high risk of bleeding undergoing to elective PCI through the femoral approach, the use of bivalirudin does not reduce the rate of in-hospital major bleeding compared to UFH. • Entry-site bleeding still represent an important issue • Radial approach should be routinely used in this subgroup of patients

  32. NAPLES III Investigators

  33. NAPLES III Investigators

More Related